Refractory Non-Hodgkin Lymphoma
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
3 drugs in development·2 companies·8 clinical trials
Drug Pipeline by Phase
Approved(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| Mosunetuzumab | BRISTOL MYERS SQUIBB CO (BMY) |
Phase 4(1)
| Drug | Company |
|---|---|
| BMS-986458 | BRISTOL MYERS SQUIBB CO (BMY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Refractory Non-Hodgkin Lymphoma?
BioSniper tracks 3 drugs in development for Refractory Non-Hodgkin Lymphoma across 2 companies.
How many clinical trials target Refractory Non-Hodgkin Lymphoma?
There are 8 clinical trials targeting Refractory Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Refractory Non-Hodgkin Lymphoma?
The estimated prevalence of Refractory Non-Hodgkin Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Refractory Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis